Board of Director's
Mohan H. Bhandari
Dr. Praful R. Naik
Chandra Prakash Jaggi
Cyrus Bagwadia
Dr. Volker Huelck
Dr. Kalyani Gandhi
Rakesh Jhunjhunwala
Manish Gupta
Rajendra Tapadia
Dr. R. V. Chaudhary
Team Bilcare is highly qualified, enthusiastic, experienced and fiercely driven by the challenge of continually working out innovatively effective solutions. Empowered in an enabling environment that provokes creativity and highest productivity, every member of the Team works to surpass personal and organisational benchmarks.
Infrastructure
Bilcare is a global provider of pharma solutions. Bilcare has the vision, manufacturing muscle, experience, expertise and service backup to create and deliver solutions that exactly meet your needs in any part of the world.
Global reach, local understanding:
All operations conform to highest
international standards
Keen understanding of local and regional issues that appropriately address R&D and business practices
ISO 9001 and 14001
USFDA
DEA
IQA
SAP
Alliances
Serving over 500 global customers, to name a few of them:
Abbott
Aventis
Cipla
GSK
Johnson & Johnson
Merck
Novartis
Pfizer
Ranbaxy
Wyeth
Zydus Cadila
Worldwide network of qualified field personnel offering prompt and localized expert assistance. Latest ERP solution from SAP in place to maintain the clock efficiency of all customer oriented proceses. Anytime communication and quickest response to requirements. OPPI best vendor award for 2002. (Organization of Pharma Producers of India)
Business Profile
Bilcare (BI) is a provider of pharmaceutical research services, clinical services and packaging systems and material. It was incorporated as a private limited company on July 1, 1987 and converted into a public limited company on Oct. 27, 1994.
The ISO 9001:2000 certified company offers research services including pre-formulation studies, formulation development, analytical research, stability studies, packaging audit, packaging development and design, and customized packaging solutions; clinical services such as project management, product and protocol design, batch manufacturing, primary packaging, labeling & randomization, kit assembly, distribution, ivrs, returns management, and controlled substances management.
Creating innovative product differentiation through packaging and vast experience of working with over 500 pharma manufacturers worldwide, the company offers global expertise in packaging development and operations. It is an established supply chain partner meeting packaging needs of leading pharma manufacturers. The state-of-the-art manufacturing and R&D facilities are located in India, Singapore and USA. It has alliances with National Chemical Laboratory, Pune for specialized research; PRS Permacel for anti-counterfeit devices and systems, Sam-A, Korea, for innovative pharma packaging foil solutions; and Precision Gears, a subsidiary of IMA, S.p.A., Italy, for an interface in packaging complexities.
The ISO 9001:2000 certified company offers research services including pre-formulation studies, formulation development, analytical research, stability studies, packaging audit, packaging development and design, and customized packaging solutions; clinical services such as project management, product and protocol design, batch manufacturing, primary packaging, labeling & randomization, kit assembly, distribution, ivrs, returns management, and controlled substances management.
Creating innovative product differentiation through packaging and vast experience of working with over 500 pharma manufacturers worldwide, the company offers global expertise in packaging development and operations. It is an established supply chain partner meeting packaging needs of leading pharma manufacturers. The state-of-the-art manufacturing and R&D facilities are located in India, Singapore and USA. It has alliances with National Chemical Laboratory, Pune for specialized research; PRS Permacel for anti-counterfeit devices and systems, Sam-A, Korea, for innovative pharma packaging foil solutions; and Precision Gears, a subsidiary of IMA, S.p.A., Italy, for an interface in packaging complexities.
Bilcare Singapore, a wholly owned subsidiary, has Bilcare GmbH, Germany; Bilcare, USA; Bilcare Farmaceutica Embalagem E Pesquisas, Brazil; Bilcare UK); Bilcare Switzerland SA; and the recently acquired Singular ID. DHP is a wholly owned subsidiary of Bilcare (UK). The company has a worldwide presence in over 20 countries covering Asia (Singapore), Europe (Frankfurt), North America (New Jersey), South America (Brazil) and others. The client list includes Abbott, Ranbaxy, Dr. Reddy`s, Aurobindo Pharma, Lupin Laboratories, Sun Pharma, Ipca Laboratory and global majors like Aventis India, Pfizer India, Novartis India, Bayer India among others.
The registered office is located at 1028, Shiroli Village, Khed taluka, Rajgurunagar, Pune-410505, Maharashtra.
Financials
Bilcare registered a 16.83% growth in net profit to Rs 165.9 million for the quarter ended December 2007 from a profit of Rs 142 million for the quarter ended December 2006.
Net sales rose 24.74% to Rs 1,041.2 million for the quarter ended December 2007 from Rs 834.7 million for the quarter ended December 2006.
Total income rose 23.39% to Rs 1,074.4 million for the quarter ended December 2007 from Rs 870.7 million for the quarter ended December 2006.
The earnings per share (EPS) of the company stood at Rs 10.08 for the quarter ended December 2007.
Future Plans
Bilcare plans more satellite research centers across the globe in various global pharmaceutical hubs. This will ensure that customers in every region of the world will have a more direct access to the technical team of Bilcare Research, leading to an enhanced speed and quality of services provided.
Bilcare`s Center of Excellence at Pune is also being expanded to cater to the significantly increasing needs of the global pharmaceutical sector.
Bilcare - Press Release
Bilcare Ltd has announced that Bilcare Singapore Pte. Ltd., wholly owned subsidiary of the Company has issued USD 90 million 4% Convertible Bonds due 2012. The bonds may be redeemed in whole at the option of the bondholder on the maturity date at a price of 130.726% of the principal amount, plus accrued interest, as per the terms of the issue. The Bonds may be converted to shares of Bilcare Singapore Pte Ltd at maturity or 90 days after the completion of a Qualified IPO. The bonds will be listed on Singapore Stock Exchange. The proceeds from the issue will be utilized for the ongoing global expansion / investment plans of the Company.
Bilcare - Allotment of Equity Shares on Conversion of FCCBs
Bilcare Ltd has informed that the Committee of Directors for Foreign Currency Convertible Bonds (FCCBs), under delegated authority on December 31, 2007 has considered and allotted 211,512 Equity Shares of Rs 10/- each upon conversion of the FCCB's issued earlier at a conversion price of Rs 880 per share, including premium.
Consequently, the Paid-up Equity Share Capital of the Company stands increased to Rs 164,530,650/- divided into 16,453,065 Equity Shares of Rs 10/- each.
Bilcare Ltd - Press Release
Bilcare Ltd has announced that Bilcare Singapore Pte Ltd has bought 100% of Singular ID, the provider of integrated high technology enterprise brand security system, for a consideration of Singapore $ 19.58 million. Bilcare Singapore Pte Ltd is a wholly owned subsidiary of the Company.
Creating and developing innovative and viable anti-counterfeit technologies & products has been one of the core Research initiatives at the Company. This acquisition underlines the importance that Bilcare places on offering state-of-the-art anti-counterfeit solutions, more particularly in the form of end user oriented and fully integrated systems.
With counterfeit products not only affecting trust and safety of the consumer, but damaging the reputation and bottom line of the industry as well, there has been a dire need for a robust and scalable anti-counterfeit solution. I am delighted to bring Singular ID into the Bilcare group and greatly strengthen our vital product offerings, explained Mr. Mohan Bhandari, Chairman and Managing Director of the Company.
Creating and developing innovative and viable anti-counterfeit technologies & products has been one of the core Research initiatives at the Company. This acquisition underlines the importance that Bilcare places on offering state-of-the-art anti-counterfeit solutions, more particularly in the form of end user oriented and fully integrated systems.
With counterfeit products not only affecting trust and safety of the consumer, but damaging the reputation and bottom line of the industry as well, there has been a dire need for a robust and scalable anti-counterfeit solution. I am delighted to bring Singular ID into the Bilcare group and greatly strengthen our vital product offerings, explained Mr. Mohan Bhandari, Chairman and Managing Director of the Company.
